Last reviewed · How we verify
NCT03717025
A Comparative Study Between Autologous Mini Punch Grafting, Suction Blister Grafting and Non-Cutured Epidermal Cell Suspension on Resistant Sites in Stable Vitiligo
NA trial testing SUCTION BLISTER EPIDERMAL GRAFTING in Vitiligo in 20 participants. Status unknown.
1 October 2018
Quick facts
| Lead sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 July 2017 |
| Primary completion | 1 October 2018 |
| Estimated completion | 1 November 2018 |
| Sites | 1 location across India |
Drugs / interventions tested
- SUCTION BLISTER EPIDERMAL GRAFTING
- MINI PUNCH GRAFTING
- NON CULTURED EPIDERMAL CELL SUSPENSION
Conditions studied
- Vitiligo — all drugs for Vitiligo →
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Who can join
18 and older, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Repigmentation At Surgery Site
Time frame: Repigmentation will be assessed at 12 weeks.
To assess the difference in extent of repigmentation of the surgery site by three different methods at 12 weeks of post treatment follow up in a given patient. Repigmentation will be assessed as follows: ≤25% Minimal repigmentation 26-50% Mild repigmentation 51-75% Moderate repigmentation 76-90% Marked repigmentation \>90% Excellent repigmentation
Sponsor's own description
Comparing the Efficacy of Three Different Surgical Methods on Resistant Sites in Stable Vitiligo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments.
Ghashghaei S, Abbaszadeh M, Karimi S, Ataie-Fashtami L, et al · · 2023 · cited 2× · PMID 37038694 · DOI 10.22074/cellj.2023.557550.1067
Verify or expand the search:
- PubMed search for NCT03717025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vitiligo
Currently open trials in the same condition.
- NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
- NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
- NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
- NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
- NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting
Other Post Graduate Institute of Medical Education and Research, Chandigarh trials
Trials by the same sponsor.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07436988 — Affordable Made-in-India Microspheres for Liver Cancer Therapy · Phase 1 · not yet recruiting
- NCT07286643 — Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis · NA · recruiting
- NCT07280390 — Microplastics, Cirrhosis and Portal Hypertension · not yet recruiting
- NCT07182877 — Comparison of Dwell Time of Open Versus Closed Type Peripheral Intravenous Cannula · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03717025 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Post Graduate Institute of Medical Education and Research, Chandigarh
- Last refreshed: 22 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing